Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
2024-06-06 07:09:15 ET More on Novartis, Roche, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Roche Is Joining The Obesity Party But Questions Remain SA Asks: Which weight-lo...
2024-06-03 17:24:06 ET Novartis AG (NVS) Investor Event at ASCO Conference Call June 02, 2024 07:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global...
2024-05-28 13:35:36 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...
2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...
2024-05-24 14:48:52 ET Summary The stock of Cytokinetics, Incorporated plunged 17% in trading on Thursday, largely as the result of a somewhat botched capital raise announcement. The capital raise took a near-term buyout off the table in the short term and left many shareholders f...
2024-05-24 10:00:00 ET Summary Dodge & Cox Stock Fund seeks long-term growth of principal and income, with a secondary focus on achieving a reasonable current income. During the first quarter of 2024, international equities performed well, especially in developed markets....
2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...
2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...
2024-04-30 12:18:17 ET More on AstraZeneca, GSK, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy AstraZeneca: Strong In A Weak Market GSK Q1 2024 Earnings Preview Ast...
2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...